Four years later: A clinical update on latanoprost

European Journal of Ophthalmology

Volumn 13, Issue 2, 2003, Pages 162-175

  Ravinet, E ^a   Mermoud, A ^a   Brignoli, R ^b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b Tradyser GmbH   (Switzerland)

Author keywords

Efficacy; Glaucoma; Latanoprost; NTG; PGF; POAG; Review; Safety; Xalatan

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRIMONIDINE; DORZOLAMIDE; LATANOPROST; TIMOLOL; TRAVOPROST; UNOPROSTONE ISOPROPYL ESTER;

AQUEOUS HUMOR FLOW; BIBLIOGRAPHIC DATABASE; CATARACT EXTRACTION; CILIARY MUSCLE; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; EXTRACELLULAR MATRIX; EYE BLOOD FLOW; FATIGUE; HUMAN; HYPEREMIA; HYPERTRICHOSIS; INTRAOCULAR FOREIGN BODY; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; IRIDECTOMY; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; RETINA MACULA CYSTOID EDEMA; REVIEW; UVEITIS; VERTIGO;

EID: 0037361239     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210301300208     Document Type: Review

References (89)

1. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol 1996; 80: 389-93.
2. Thylefors B, Negrel AD. The global impact of glaucoma. Bull World Health Organ 1994; 72: 323-6.
3. Wensor MD, McCarty CA, Stanislavsky YL, Livingston PM, Taylor HR. The prevalence of glaucoma in the Melbourne visual impairment project. Ophthalmology 1998; 105: 733-9.
4. Damji KF. Advances in molecular genetics of glaucoma: A perspective for the clinician. Semin Ophthalmol 1999; 14: 171-9.
5. Camras CB, Alm A. Initial clinical studies with prostaglandins and their analogues. Surv Ophthalmol 1997; 41 (Suppl): S61-8.
6. Sjoquist B, Johansson A, Stjernschantz J. Pharmacokinetics of latanoprost in the cynomolgus monkey. 3rd communication: tissue distribution after topical administration on the eye studied by whole body autoradiography. Glaucoma Research Laboratories. Arzneimittelforschung 1999; 49: 240-9.
7. Sjoquist B, Tajallaei S, Stjernschantz J. Pharmacokinetics of latanoprost in the cynomolgus monkey. 1st communication: single intravenous, oral or topical administration on the eye. Arzneimittelforschung 1999; 49: 225-33.
8. Sjoquist B, Uhlin A, Byding P, Stjernschantz J. Pharmacokinetics of latanoprost in the cynomolgus monkey. 2nd communication: repeated topical administration on the eye. Arzneimittelforschung 1999; 49: 234-9.
9. Hejkal TW, Camras CB. Prostaglandin analogs in the treatment of glaucoma. Semin Ophthalmol 1999; 14: 114-23.
10. Sagara T, Gaton DD, Lindsey JD, Gabelt BT, Kaufman PL, Weinreb RN. Topical prostaglandin F2alpha treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch Ophthalmol 1999; 117: 794-801.
11. Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp Eye Res 1998; 67: 179-91.
12. Hassard A, Tingey DP, Cargill D, Motolko M. The intraocular pressure lowering effect of latanoprost varies with anterior segment structures. Invest Ophthalmol Vis Sci, 2001; 42: A2248.
13. Martin L. Clinical experience with latanoprost: a retrospective study of 153 patients. Acta Ophthalmol 1999; 77: 336-9.
14. Camras CB, Alm A, Watson ID, Stjernschantz J. Latanoprost: a prostaglandin analog for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups. Ophthalmology 1996; 103: 1916-24.
15. Suzuki M, Mishima HK, Masuda K, Araie M, Kitazawa Y, Azuma I. Efficacy and safety of latanoprost eye drops for glaucoma treatment: A 1-year study in Japan. Jpn J Ophthalmol 2000; 44: 33-8.
16. Watson PG. Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group. Ophthalmology 1998; 105: 82-7.
17. Alm A, Widengard I. Latanoprost: experience of 2-year treatment in Scandinavia. Acta Ophthalmol 2000; 78: 71-6.
18. Stewart WC, Sharpe ED, Day DG, et al. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta- adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2000; 16-3: 251-9.
19. Shin DH, McCracken MS, Bendel RE, et al. The additive effect of latanoprost to maximum-tolerated medications with low-dose, highdose, or no pilocarpine therapy. Ophthalmology 1999; 106-2: 386-90.
20. Krag S, Andersen HB, Sorensen T. Circadian intraocular pressure variation with beta-blockers. Acta Ophtalmol 1999; 77: 500-3.
21. Racz P, Ruzsonyi MR, Nagy ZT, Gaygi Z, Bito LZ. Around-the-clock intraocular pressure reduction with once-daily application of latanoprost by itself or in combination with timolol. Arch Ophthalmol 1996; 114: 268-73.
22. Orzalesi N, Rossetti L, Invernizzi T, Bottoli A, Autelitano A. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci 2000; 41: 2566-73.
23. Kuwayama Y, Itoh N, Kano K, et al. Comparison of timolol and latanoprost in diurnal variation of hypotensive effect. Invest Ophthalmol Vis Sci 2001; 42: A4396.
24. Stewart WC, Day DG, Sharpe ED, Dubiner HB, Holmes KT, Stewart JA. Efficacy and safety of timolol solution once daily vs timolol gel added to latanoprost. Am J Ophthalmol 1999; 128-6: 692-6.
25. Diestelhorst M, Almegard B. Comparison of two fixed combinations of latanoprost and timolol in open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol 1998; 236-8: 577-81.
26. Pfeiffer N, Yannoulis N, Mertz B, Cirkel C, Kapik B. The unoprostone Study Group. Efficacy and safety of unoprostone isopropyl 0.15% and latanoprost 0.005% in adjunctive therapy to timolol maleate 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci 2001; 42: A4398.
27. Susanna R Jr, Nicolela MT, Oga E. Additive effect of latanoprost to the combination of timolol and dorzolamide. J Glaucoma 2000; 9: 183-6.
28. Simmons ST, Samuelson TW. Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma. Alphagan/Xalatan Study Group. Clin Ther 2000; 22: 388-99.
29. Vetrugno M, Cantatore F, Gigante G, Cardia L. Latanoprost 0.005% in POAG: Effects on IOP and ocular blood flow. Acta Ophthalmol 1998; 227 (Suppl): S40-1.
30. Sponsel WE, Paris G, Trigo Y, et al. Latanoprost and brimonidine: Therapeutic and physiologic assessment before and after oral nonsteroidal anti-inflammatory therapy. Am J Ophthalmol 2002; 133: 11-8.
31. Nicolela MT, Buckley AR, Walman BE, Drance SM. A comparative study of the effects of timolol and latanoprost on blood flow velocity of the retrobulbar vessels. Am J Ophthalmol 1996; 122: 784-9.
32. Hedman K, Alm A. A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Eur J Ophthalmol 2000; 10: 95-104.
33. O'Donoghue EP. A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: a 3 month, randomised study. Ireland Latanoprost Study Group. Br J Ophthalmol 2000;84: 579-82.
34. Spiegel D, European Latanoprost Study Group. A comparison of the safety and efficacy of latanoprost (Xalatan®) versus the fixed combination of dorzolamide and timolol (Cosopt®) in patients with open angle glaucoma. Invest Ophthalmol Vis Sci 2001; 42: A4414.
35. DuBosar U. Latanoprost once daily significantly more effective than brimonidine twice daily. Ocular Surgery News 2000, 80.
36. Stewart WC, Day DG, Stewart JA, Holes KT, Leech JN, Rowan CT, Schwartz GF. Therapeutic success of latanoprost 0.005% compared tp brimonidine 0.2% in patients with open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2000; 16: 557-63.
37. Susanna R, Giampani J, Borges AS, Vessani RM, Jordao MLS. A double masked, randomized clinical trial comparing with unoprostone in patients with open-angle glaucoma or ocular hypertension. Ophthalmology 2001, 108: 259-63.
38. Yamamoto T, Kitazawa Y. Iris color change developed after topical isopropyl unoprostone treatment. J Glaucoma 1997; 6: 430-2.
39. Eisenberg DL, Camras CB. A preliminary risk-benefit assessment of latanoprost and unoprostone in open-angle glaucoma and ocular hypertension. Drug Saf 1999; 20: 505-14.
40. Yip LW, Aung T, Chew PTK, et al. Additive effect of unoprostone and latanprost in patients with elevated intraocular pressure. Invest Ophthalmol Vis Sci 2001; 42: A2257.
41. Kiuchi Y, Fukui K, Ohnishi T, Hayashida Y, Ichiro I. Additive ocular hypotensive effect of latanoprost and unoprostone in patients with open angle glaucoma. Invest Ophthalmol Vis Sci 2001; 42: A4394.
42. Netland PA, Landry T, Silver LH, et al. IOP lowering efficacy and safety of travoprost compared to latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci 2001; 42: A2984.
43. Higginbotham EJ. The expanding field of prostaglandin analogs. Review of Ophthalmology 2001; 8: 117-21.
44. Bucci MG. Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: A randomized, observer-masked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study Group. J Glaucoma 1999; 8-1: 24-30.
45. Nordmann JP, Soderstrom M, Rouland JF, Malecaze F. Comparison of the intraocular pressure lowering effect of latanoprost and a fixed combination of timolol-pilocarpine eye drops in patients insufficiently controlled with beta adrenergic antagonists. French Latanoprost Study Group, and the Swedish Latanoprost Study Group. Br J Ophthalmol 2000; 84: 181-5.
46. Emmerich KH. A comparison of latanoprost monotherapy to dorzolamide combined with timolol in glaucoma and ocular hypertension patients. New Orleans: Am Acad Ophthalmology, 1998.
47. Fuchs M, The Latanoprost Drug Observation Group. Latanoprost: Efficacy and safety in a 6 months observational study. Invest Ophthalmol Vis Sci 2001; 42: A2242.
48. Kent AR, Vroman DT, Thomas TJ, Hebert RL, Crosson CE. Interaction of pilocarpine with latanoprost in patients with glaucoma and ocular hypertension. J Glaucoma 1999; 8: 257-62.
49. Rulo AH, Greve EL, Geijssen HC, Hoyng PFJ. Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal pressure glaucoma. Ophthalmology 1996; 103: 1276-82.
50. Tamada Y, Taniguchi T, Murase H, Yamamoto T, Kitazawa Y. Intraocular pressure-lowering efficacy of latanoprost in patients with normal-tension glaucoma or primary open-angle glaucoma. J Ocul Pharmacol Ther 2001; 17: 19-25.
51. Greve EL, Rulo AH, Drance SM, Crichton AC, Mills RP, Hoyng PF. Reduced intraocular pressure and increased ocular perfusion pressure in normal tension glaucoma: a review of short-term studies with three dose regimens of latanoprost treatment. Surv Ophthalmol 1997; 41 (Suppl): S89-92.
52. Drance SM, Crichton A, Mills RW. Ocular perfusion pressure in normal tension glaucoma patients after latanoprost or timolol treatment. Chicago: Am Acad Ophthalmology, 1996.
53. Drance SM, Crichton A, Mills RP. Comparison of the effect of latanoprost 0.005% and timolol 0.5% on the calculated ocular perfusion pressure in patients with normal-tension glaucoma. Am J Ophthalmol 1998; 125: 585-92.
54. Garzozi H, Harris A, Kagemann L, et al. Comparison of dorzolamide and latanoprost in normal-tension glaucoma: Effects on IOP and retinal hemodynamics. Invest Ophthalmol Vis Sci 2001; 42: A125.
55. Aung T, Wong HAT, Yip CC, Leong JY, Chan YH, Chew PT. Comparison of the intraocular pressure-lowering effect of latanoprost and timolol in patients with chronic angle closure glaucoma: A preliminary study. Ophthalmology 2000; 107: 1178-83.
56. Hung PT, Hsieh JW, Chen YF, Wei T. Efficacy of latanoprost as an adjunct to medical therapy for residual angle-closure glaucoma after iridectomy. J Ocul Pharmacol Ther 2000; 16-1: 43-7.
57. Mastropasqua L, Carpineto P, Ciancaglini M, Gallenga PE. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma. Ophthalmology 1999; 106: 550-5.
58. Scherer WJ, Mielke DL, Tidwell PE, Hauber FA. Effect of latanoprost on intraocular pressure following cataract extraction (see comments). J Cataract Refract Surg 1998; 24: 964-7.
59. Lai JS, Chua JK, Leung AT, Lam DS. Latanoprost versus timolol gel to prevent ocular hypertension after phacoemulsification and intraocular lens implantation. J Cataract Refract Surg 2000; 26: 386-91.
60. Rainer G, Menapace R, Schmetterer K, Findl O, Georgopoulos M, Vass C. Effect of dorzolamide and latanoprost on intraocular pressure after small incision cataract surgery. J Cataract Refract Surg 1999; 25: 1624-9.
61. Scherer WJ, Hauber FA. Effect of latanoprost on intraocular pressure in steroid-induced glaucoma. J Glaucoma 2000; 9: 179-82.
62. Gaddie IB, Bennett DW. Cystoid macular edema associated with the use of latanoprost. J Am Optom Assoc 1998; 69: 122-8.
63. Fechtner RD, Khouri AS, Zimmerman TJ, et al. Anterior uveitis associated with latanoprost. Am J Ophthalmol 1998; 126: 37-41.
64. Enyedi LB, Freedman SF, Buckley EG. The effectiveness of latanoprost for the treatment of paediatric glaucoma. J AAPOS 1999; 3: 33-9.
65. Mertts M, Garfield S, Tanemoto K, Tomarev SI. Identification of the region in the N-terminal domain responsible for the cytoplasmic localization of Myoc/Tigr and its association with microtubules. Lab Invest 1999; 79: 1237-45.
66. Altuna JC, Greenfield DS, Wand M, et al. Latanoprost in glaucoma associated with Sturge-Weber syndrome: Benefits and side-effects. J Glaucoma 1999; 8: 199-203.
67. Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology 1998; 105: 263-8.
68. Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol 1997; 124: 544-7.
69. Camras CB, Neely DG, Weiss EL. Latanoprost-induced iris color darkening: A case report with long-term follow-up. J Glaucoma 2000; 9: 95-8.
70. Dutkiewicz R, Albert DM, Levin LA. Effects of latanoprost on tyrosinase activity and mitotic index of cultured melanoma lines. Exp Eye Res 2000; 70: 563-9.
71. Drago F, Marino A, La Manna C. Alpha-Methyl-p-tyrosine inhibits latanoprost-induced melanogenesis in vitro. Exp Eye Res 1999; 68: 85-90.
72. Smith SL, Pruitt CA, Sine CS, Hudgins AC, Stewart WC. Latanoprost 0.005% and anterior segment uveitis. Acta Ophthalmol 1999; 77: 668-72.
73. Saccà S, Pascotto A, Siniscalchi C, Rolando M. Ocular complications of latanoprost in uveitic glaucoma, three case reports. J Ocul Pharmacol Ther 2001; 17: 107-13.
74. Ardjomand N, Aigner R, El-Shabrawi Y. The role of latanoprost in intraocular inflammation revisited. Invest Ophthalmol Vis Sci 2001; 42: A3980.
75. Schumer RA, Camras CB, Mandahl AK. Latanoprost and cystoid macular edema: is there a causal relation? Curr Opin Ophthalmol 2000; 11-2: 94-100.
76. Miyake K, Ota I, Ibaraki N, et al. Enhanced disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema by topical timolol and its preservative in early postoperative pseudophakia. Arch Ophthalmol 2001; 119: 387-94.
77. Miyake K, Ota I, Maekubo K, Ichihashi S, Miyake S. Latanoprost accelerates disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema in early postoperative pseudophakias. Arch Ophthalmol 1999; 117: 34-40.
78. Thygesen J, Aaen K, Theodorsen F, Kessing SV, Prause JU. Short-term effect of latanoprost and timolol eye drops on tear fluid and the ocular surface in patients with primary open-angle glaucoma and ocular hypertension. Acta Ophthalmol Scand 2000; 78: 37-44.
79. Wand M, Gilbert CM, Liesegang TJ. Latanoprost and herpes simplex keratitis. Am J Ophthalmol 1999; 127: 602-4.
80. Stewart O, Walsh L, Pande M. Bilateral optic disc oedema associated with latanoprost (Letter). Br J Ophthalmol 1999; 83: 1092-3.
81. Aslanides IM. Bilateral optic disc oedema associated with latanoprost (letter). Br J Ophthalmol 2000; 84: 673.
82. Veyrac G, Chiffoleau A, Cellerin L, Larousse C, Bourin M. Latanoprost (Xalatan) and a systemic respiratory effect? Apropos of a case (letter). Latanoprost (Xalatan) et effet systemique respiratoire? A propos d'un cas. Therapie 1999; 54: 494-6.
83. Linden C, Nuija E, Alm A. Effects on IOP restoration and blood-aqueous barrier after long-term treatment with latanoprost in open angle glaucoma and ocular hypertension. Br J Ophthalmol 1997; 81: 370-2.
84. Asrani S, Zeimer R, Wilensky J, Giesser D, Vitale S, Lindenmuth K. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 2000; 9: 134-42.
85. Flammer J, Robert Y, Gloor B. Influence of pindolol and timolol treatment on the visual fields of glaucoma patients. J Ocul Pharmacol 1986; 2: 305-11.
86. Messmer C, Flammer J, Stumpfig D. Influence of betaxolol and timolol on the visual fields of patients with glaucoma. Am J Ophthalmol 1991; 15: 678-81.
87. Kaiser HJ, Flammer J, Stumpfig D, Hendrickson P. Longterm visual field follow-up of glaucoma patients treated with beta-blockers. Surv Ophthalmol 1994; 38-156-9: 160.
88. Flammer J, Kitazawa Y, Bonomi L, et al. Influence of carteolol and timolol on IOP and visual fields in glaucoma: a multi-center, doublemasked, prospective study. Eur J Ophthalmol 1992; 2: 169-74.
89. Mermoud A. Modern anti-glaucoma drugs and their secondary effects. Les médicaments antiglaucomateux modernes et leurs effets secondaires. Rev Med Suisse Romande 1998; 118: 937-40.